(CHRS) Coherus BioSciences - Ratings and Ratios

Coherus BioSciences, Inc. (NASDAQ: CHRS) is a biopharmaceutical company focused on the research, development, and commercialization of innovative cancer treatments and biosimilars. The company specializes in immuno-oncology and has a pipeline that includes both biosimilars and novel biologic therapies. Its lead products include UDENYCA, a biosimilar to Neulasta, which is used to reduce the incidence of infection in patients undergoing chemotherapy; LOQTORZI, a novel PD-1 inhibitor designed to target cancer cells while minimizing side effects; and Casdozokitug, an investigational monoclonal antibody targeting interleukin 27, which plays a role in the immune response to cancer. Additionally, the company is developing CHS-114, a highly specific antibody targeting CCR8, a receptor expressed on Treg cells in the tumor microenvironment, and CHS-1000, an antibody targeting human ILT4 to enhance the efficacy of anti-PD-1 therapies. Coherus also offers YUSIMRY, a biosimilar to Humira, for the treatment of inflammatory diseases such as rheumatoid arthritis, psoriasis, and Crohns disease.

The company has established strategic collaborations, including a co-development agreement with Junshi Biosciences for toripalimab, a PD-1 inhibitor; a licensing agreement with Bioeq AG for YUSIMRY; and partnerships with Surface Oncology and Adimab LLC for antibody discovery. Coherus also has out-licensing agreements with Novartis and GlaxoSmithKline. The company, originally founded as BioGenerics, Inc. in 2010 and renamed Coherus BioSciences, Inc. in 2012, is headquartered in Redwood City, California, and operates with a focus on improving patient access to affordable and innovative therapies.